康泰生物：四价流感病毒裂解疫苗（6-35月龄人群）开启Ⅰ期临床试验

Core Viewpoint - Kangtai Biological (300601) has announced the initiation of Phase I clinical trials for its quadrivalent influenza virus split vaccine targeting the 6-35 month age group, with the first subject successfully enrolled [1] Group 1 - The company has completed preparations for the Phase I clinical trial of the quadrivalent influenza vaccine [1] - The clinical trial is now officially underway following the successful enrollment of the first participant [1]